3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
4
Recurrence
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
Cyclophosphamide
72
Cytarabine
61
fludarabine phosphate
48
venetoclax
42
Peripheral Blood Stem Cell Transplantation
37
fludarabine
34
Busulfan
31
Methotrexate
29
Cyclosporine
29
Mycophenolic Acid
28
Filgrastim
27
Azacitidine
27
Antilymphocyte Serum
26
Whole-Body Irradiation
22
Etoposide
21
Radiotherapy
20
Melphalan
20
Tacrolimus
19
Rituximab
19
Dexamethasone
16
Methylprednisolone
15
Granulocyte Colony-Stimulating Factor
15
Decitabine
15
Vincristine
14
Cord Blood Stem Cell Transplantation
14
Doxorubicin
13
Clofarabine
11
Mitoxantrone
10
ibrutinib
9
blinatumomab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Infusions, Intravenous
×
Other hematologic neoplasm
×
Clear all
NCT03850574
2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2
Recruiting
240 enrolled